Literature DB >> 22281285

Comparison of the prognostic predictive value of the TIMI, PAMI, CADILLAC, and GRACE risk scores in STEACS undergoing primary or rescue PCI.

Elizabet Méndez-Eirín1, Xacobe Flores-Ríos, Fernando García-López, Alberto J Pérez-Pérez, Rodrigo Estévez-Loureiro, Pablo Piñón-Esteban, Guillermo Aldama-López, Jorge Salgado-Fernández, Ramón A Calviño-Santos, José M Vázquez Rodríguez, Nicolás Vázquez-González, Alfonso Castro-Beiras.   

Abstract

INTRODUCTION AND
OBJECTIVES: We sought to compare the predictive value of the Thrombolysis In Myocardial Infarction (TIMI), Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC), Primary Angioplasty in Myocardial Infarction (PAMI), and Global Registry for Acute Coronary Events (GRACE) scores for the outcome of ST-segment elevation acute coronary syndrome undergoing urgent percutaneous coronary intervention.
METHODS: We performed a retrospective analysis of a cohort composed of all consecutive patients with ST-segment elevation acute coronary syndrome treated by urgent percutaneous coronary intervention between 2006 and 2010 (n=1503). TIMI, PAMI, CADILLAC, and GRACE risk scores were calculated for each patient according to different clinical variables. We assessed the predictive accuracy of these scores for death, reinfarction, and target-vessel revascularization at 30 days and 1 year, using the C statistic, which was obtained by means of logistic regression and ROC curves.
RESULTS: The TIMI, PAMI, CADILLAC and GRACE showed an excellent predictive value for 30-day and 1-year mortality (C statistic range, 0.8-0.9), with superiority of the TIMI, CADILLAC, and GRACE risk models. The performance of these 4 scores was poor for both reinfarction and target-vessel revascularization (C statistic, 0.5-0.6).
CONCLUSIONS: The TIMI, PAMI, CADILLAC, and GRACE scores provide excellent information to stratify the risk of mortality in patients treated by percutaneous coronary intervention. The TIMI, CADILLAC, and GRACE models have higher predictive accuracy. The usefulness of these models for reinfarction and target-vessel revascularization prediction is questionable. Copyright Â
© 2011 Sociedad Española de Cardiología. Published by Elsevier Espana. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22281285     DOI: 10.1016/j.recesp.2011.10.019

Source DB:  PubMed          Journal:  Rev Esp Cardiol (Engl Ed)        ISSN: 1885-5857


  5 in total

1.  Risk stratification and prognostic value of grace and timi risk scores for female patients with non-st segment elevation acute coronary syndrome.

Authors:  Hang Zhu; Hao Xue; Haotian Wang; Yundai Chen; Shanshan Zhou; Feng Tian; Shunying Hu; Jing Wang; Junjie Yang; Tao Zhang
Journal:  Int J Clin Exp Med       Date:  2015-03-15

2.  Predictive Power of In-Hospital and Long-Term Mortality of the GRACE, TIMI, Revised CADILLAC and PAMI Score in NSTEMI Patients with Diabetes - Data from TSOC ACS-DM Registry.

Authors:  Chih-Wei Chen; Yi-Chen Hsieh; Ming-Hsiung Hsieh; Yung-Kuo Lin; Chun-Yao Huang; Jong-Shiuan Yeh
Journal:  Acta Cardiol Sin       Date:  2020-11       Impact factor: 2.672

3.  ACTION (acute coronary treatment and intervention outcomes network) registry-GWTG (get with the guidelines) risk score predicts long-term mortality in acute myocardial infarction.

Authors:  Tongtong Yu; Chunyang Tian; Jia Song; Dongxu He; Zhijun Sun; Zhaoqing Sun
Journal:  Oncotarget       Date:  2017-10-11

4.  Acute coronary syndromes in 2011 and 2012.

Authors:  Juan Sanchis; Antoni Bayes-Genis; Leopoldo Pérez de Isla
Journal:  Arq Bras Cardiol       Date:  2013-11       Impact factor: 2.000

5.  Evaluation and Comparison of the STIMUL Extended and Simplified Risk Scores for Predicting Two-Year Death in Patients Following ST-Segment Elevation Myocardial Infarction.

Authors:  Svitlana Korol; Agnieszka Wsol; Alexander Reshetnik; Alexander Krasyuk; Kateryna Marushchenko; Liana Puchalska
Journal:  Medicina (Kaunas)       Date:  2021-12-10       Impact factor: 2.430

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.